Skye Bioscience (NASDAQ:SKYE) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.31) by 3.23 percent. This is a 14.29 percent decrease over losses of $(0.28) per share from the same period last year.